OGT to Exhibit its Tailored Biomarker Discovery Solutions at Companion Diagnostics 2011 in Frankfurt
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be attending this year’s Companion Diagnostics Summit Europe in Frankfurt (22nd to 24th March).
Will Colón (Business Development Director, Biomarker Discovery) and Graham Speight (Head of Genomic Biomarkers) will be present to talk with delegates about OGT’s tailored biomarker discovery solutions.
The aim of the meeting is to discuss the best way to convert biomarker research into more accurate diagnostic methods and safer and more successful drug treatment strategies.
OGT has already had significant success developing reliable and accurate solutions as part of its in-house biomarker discovery programmes, targeting diseases such as prostate cancer, systemic lupus erythematosus (SLE) and colorectal cancer.
Will Colón (Business Development Director, Biomarker Discovery) and Graham Speight (Head of Genomic Biomarkers) will be present to talk with delegates about OGT’s tailored biomarker discovery solutions.
The aim of the meeting is to discuss the best way to convert biomarker research into more accurate diagnostic methods and safer and more successful drug treatment strategies.
OGT has already had significant success developing reliable and accurate solutions as part of its in-house biomarker discovery programmes, targeting diseases such as prostate cancer, systemic lupus erythematosus (SLE) and colorectal cancer.
